Elmind Capital LP Purchases New Shares in Entero Therapeutics, Inc. $ENTO

Elmind Capital LP acquired a new stake in Entero Therapeutics, Inc. (NASDAQ:ENTO) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 210,000 shares of the company’s stock, valued at approximately $363,300,000. Elmind Capital LP owned approximately 13.22% of Entero Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also modified their holdings of the company. ADAR1 Capital Management LLC purchased a new stake in shares of Entero Therapeutics during the 2nd quarter worth about $3,642,000. Persistent Asset Partners Ltd purchased a new position in shares of Entero Therapeutics in the 2nd quarter valued at about $198,000. GSA Capital Partners LLP acquired a new position in Entero Therapeutics in the 2nd quarter worth about $65,000. Finally, Virtu Financial LLC acquired a new position in Entero Therapeutics in the 3rd quarter worth about $59,000. Institutional investors and hedge funds own 12.30% of the company’s stock.

Entero Therapeutics Trading Up 2.3%

Shares of ENTO stock opened at $3.65 on Wednesday. Entero Therapeutics, Inc. has a 12-month low of $0.32 and a 12-month high of $5.84. The business’s 50 day moving average is $3.84 and its two-hundred day moving average is $3.41. The company has a market capitalization of $5.80 million, a P/E ratio of -2.16 and a beta of 1.19.

Entero Therapeutics Company Profile

Entero Therapeutics, Inc (NASDAQ: ENTO) is a clinical‐stage specialty pharmaceutical company dedicated to developing innovative therapies for patients suffering from rare and debilitating gastrointestinal (GI) disorders. The company leverages targeted delivery technologies designed to localize therapeutic molecules directly to affected regions of the GI tract, aiming to enhance efficacy while minimizing systemic exposure. Entero’s research and development efforts focus on addressing chronic conditions with significant unmet medical needs, including malabsorption syndromes and motility‐related GI diseases.

Entero’s pipeline features multiple lead candidates in varying stages of clinical development.